Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study
Journal of Cystic Fibrosis · 2024-01 · 23 (1) · 41-49
DOI: 10.1016/j.jcf.2023.05.003 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cystic Fibrosis, 2024-01. Verfasst von Vered Wiesel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical School for International Health, Ben Gurion University, Beer Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, B…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous, Benzodioxoles. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The prevalence of nontuberculous mycobacteria (NTM) infections is rising in people with cystic fibrosis (pwCF). NTM infection, especially infection with Mycobacterium abscessus complex (MABC), is commonly associated with severe lung deterioration. The current treatment modalities, including multiple intravenous antibiotics, frequently fail to achieve airway eradication. Although treatment with elexacaftor/tezacaftor/ivacaftor (ETI) has been shown to modulate the lung microbiome, data regarding its role in eradicating NTM in pwCF is lacking. Our aim was to evaluate the impact of ETI on the rate of NTM eradication in pwCF. METHODS: This retrospective multicenter cohort study included pwCF from five CF centers in Israel. PwCF aged older than 6 who had at least one positive NTM airway culture in the past two years and were treated with ETI for at least one year were included. The annual NTM and bacterial isolations, pulmonary function tests, and body mass index were analyzed before and after ETI treatment. RESULTS: Fifteen pwCF were included (median age 20.9 years, 73.3% females, 80% pancreatic insufficient). In nine patients (66%) NTM isolations were eradicated following treatment with ETI. Seven of them had MABC. The median time between the first NTM isolation and treatment with ETI was 2.71 years (0.27-10.35 years). Eradication of NTM was associated with improved pulmonary function tests (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School for International Health, Ben Gurion University, Beer Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
- Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Pediatric Pulmonary Unit, Soroka University Medical Center, Beer Sheva, Israel.
- Kathy and Lee Graub Cystic Fibrosis Center, Schneider Children's Medical Center of Israel, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Pediatric Pulmonary Unit and Cystic Fibrosis Center, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
- Pediatric Pulmonary Institute and CF Center, Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
- Pediatric Pulmonology Unit and CF center, Carmel Medical Center, Haifa, Israel.
Zitieren
APA
Wiesel, V., Aviram, M., Mei-Zahav, M., Dotan, M., Prais, D., Cohen-Cymberknoh, M., Gur, M., Bar-Yoseph, R., Livnat, G., Goldbart, A., Hazan, G., Hazan, I., & Golan-Tripto, I. (2024). Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study. Journal of Cystic Fibrosis, 23(1), 41-49. https://doi.org/10.1016/j.jcf.2023.05.003
Vancouver
Wiesel V, Aviram M, Mei-Zahav M, Dotan M, Prais D, Cohen-Cymberknoh M, et al. Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study. Journal of Cystic Fibrosis. 2024;23(1):41-49. doi:10.1016/j.jcf.2023.05.003
BibTeX
@article{Wiesel2024,
author = {Wiesel, Vered and Aviram, Micha and Mei-Zahav, Meir and Dotan, Miri and Prais, Dario and Cohen-Cymberknoh, Malena and Gur, Michal and Bar-Yoseph, Ronen and Livnat, Galit and Goldbart, Aviv and Hazan, Guy and Hazan, Itai and Golan-Tripto, Inbal},
title = {Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study},
journal = {Journal of Cystic Fibrosis},
year = {2024},
volume = {23},
number = {1},
pages = {41--49},
doi = {10.1016/j.jcf.2023.05.003}
}
EUVIMED